Vanda Pharmaceuticals (VNDA) Tax Provisions (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 12 years of Tax Provisions data on file, last reported at $100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 101.27% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $89.8 million (up 888.07% YoY), and the FY2025 full-year result was $81.8 million, up 2134.99% from the prior year.
• Tax Provisions slipped to $100000.0 in Q1 2026, from $103.2 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $103.2 million in Q4 2025 to a low of -$7.9 million in Q1 2025.
• A 5-year average of $5.1 million and a median of -$257000.0 in 2023 frame the typical range for Tax Provisions.
• Peak annual rise in Tax Provisions reached 6465.52% in 2025, while the deepest fall reached 1420.08% in 2025.
• Tracing VNDA's Tax Provisions over 5 years: stood at $2.8 million in 2022, then slumped by 73.47% to $730000.0 in 2023, then tumbled by 322.05% to -$1.6 million in 2024, then soared by 6465.52% to $103.2 million in 2025, then slumped by 99.9% to $100000.0 in 2026.
• Business Quant data shows VNDA's Tax Provisions at $100000.0 in Q1 2026, $103.2 million in Q4 2025, and -$5.8 million in Q3 2025.